UnitedHealthcare (UHC) backs away from its biosimilar inclusion policy after the American Academy of Ophthalmology (AAO) raises concerns about safety and lack of clinical evidence.
UnitedHealthcare (UHC) has changed its policy to indicate that the bevacizumab biosimilars Mvasi and Zirabev will not be covered in the treatment of certain ophthalmic conditions or considered ophthalmically equivalent to Avastin, the reference product.
The policy change drew a statement of relief from the American Academy of Ophthalmology (AAO), which has sought to emphasize that its membership has more confidence in Avastin, given the weight of clinical evidence supporting its use for ophthalmic conditions vs the relative scarcity or outright lack of evidence supporting the use of bevacizumab biosimilars for these particular conditions.
AAO is concerned that bevacizumab biosimilars have not yet been qualified as being as safe and efficacious in ophthalmology. The group, which represents 32,000 eye physicians and surgeons, is opposing decisions by many payers to treat the bevacizumab biosimilars as equivalent to Avastin in ophthalmology.
Originally indicated and FDA-approved for the treatment of certain cancers, Avastin is not indicated for ophthalmic conditions such as age-related macular degeneration, macular edema, neovascular glaucoma and others, but it has long been used for treatment of these diseases. The difference is the weight of clinical studies that have specifically evaluated Avastin for these uses, the AAO states.
“The academy commends UnitedHealthcare for acting quickly to clarify its policy regarding the use of 2 biosimilars untested for ophthalmic/intravitreal use as alternatives to the sight-saving drug Avastin,” the AAO said.
Biosimilars are often extrapolated for use in conditions they are not directly indicated for, and this extrapolation is typically for conditions for which the reference drugs got FDA clearance. The use of bevacizumab in ophthalmology is an exception because Genentech, Avastin’s maker, has never sought FDA approval for ophthalmic conditions. Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that retards growth of blood vessels; excess growth can cause blindness and other vision problems.
In ophthalmic uses, the drug is administered intravitreally, or via injection in the eye; and the drug must be sent to compounding pharmacies to be specially prepared for this type of dosage, which raises additional concerns about safety and purity, the AAO has stated.
UHC changed its policy recently after meeting with the AAO to discuss the issue. “Anti-VEGFs are critically important treatment options for patients facing vision-threatening diseases....We appreciate the insurer’s willingness to listen to our position and to clarify policy language to protect patients,” the AAO stated.
In a policy update Tuesday, August 17, 2021, UHC said it had revised its list of covered VEGF inhibitors to exclude Mvasi and Zirabev, which are Amgen and Pfizer products, respectively.
For an interview about this issue with George Williams, MD, clinical spokesman for the AAO, click here.
For an article about payer responses and related issues, click here.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.